Stayble Therapeutics publishes interim report for the first quarter
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the first quarter of 2022. The interim report is available as an attached document and on the Company's website.Highlights during the first quarter (January – March 2022) · Stayble comments on the Company's ongoing Phase IIb clinical trial, which is ongoing in for example Russia. The Company is closely monitoring the progress and believes that the study can continue without risk to patient safety, quality or conduct. This means that the Company continues to follow the previously communicated